Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY25 results · Apr–Jun 2024
Neuland Laboratories reported revenue from operations of ₹439.60 crore (up 21.1% from Q1 FY24) and net profit of ₹97.87 crore (up 58.2% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.60 | 362.99 | +21.1% | 385.01 | +14.2% |
| Other income | 4.81 | 2.04 | +135.8% | 5.36 | −10.3% |
| Total income | 444.41 | 365.03 | +21.7% | 390.37 | +13.8% |
| Profit before tax | 129.84 | 83.16 | +56.1% | 92.20 | +40.8% |
| Net profit for the period | 97.87 | 61.88 | +58.2% | 67.56 | +44.9% |
| EPS, basic (₹) | 76.28 | 48.23 | +58.2% | 52.66 | +44.9% |
| Net margin (%) | 22.3 | 17.0 | 17.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.60 | 362.99 | +21.1% | 385.01 | +14.2% |
| Other income | 4.81 | 2.04 | +135.8% | 5.36 | −10.3% |
| Total income | 444.41 | 365.03 | +21.7% | 390.37 | +13.8% |
| Profit before tax | 130.31 | 83.50 | +56.1% | 92.08 | +41.5% |
| Net profit for the period | 98.34 | 62.22 | +58.0% | 67.61 | +45.5% |
| EPS, basic (₹) | 76.65 | 48.50 | +58.0% | 52.70 | +45.4% |
| Net margin (%) | 22.4 | 17.1 | 17.6 |
Consolidated
- Filed with BSE
- 02 Aug 2024, 17:27 IST
- Board meeting
- 01 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Aug 2024, 17:27 IST
- Board meeting
- 01 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE